Literature DB >> 12740576

NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases.

Simona Zompi1, Jessica A Hamerman, Kouetsu Ogasawara, Edina Schweighoffer, Victor L J Tybulewicz, James P Di Santo, Lewis L Lanier, Francesco Colucci.   

Abstract

In activated mouse natural killer (NK) cells, the NKG2D receptor associates with two intracellular adaptors, DAP10 and DAP12, which trigger phosphatidyl inositol 3 kinase (PI3K) and Syk family protein tyrosine kinases, respectively. Here we show that cytotoxicity, but not cytokine production, is triggered by NKG2D in activated NK cells lacking either DAP12 or the Syk family members Syk and ZAP70. Inhibition of PI3K blocks this cytotoxicity, suggesting that the DAP10-PI3K pathway is sufficient to initiate NKG2D-mediated killing of target cells. Our results highlight signaling divergence in the effector functions of NKG2D and indicate that alternative associations between a receptor and its adaptors may provide a single receptor with a dual 'on-switch', giving mouse NK cells more choices through which to trigger cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740576     DOI: 10.1038/ni930

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  59 in total

1.  Differential effects of stimulatory factors on natural killer cell activities of young and aged mice.

Authors:  Shoko Nogusa; Donna M Murasko; Elizabeth M Gardner
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-27       Impact factor: 6.053

Review 2.  Current perspectives of natural killer cell education by MHC class I molecules.

Authors:  Petter Höglund; Petter Brodin
Journal:  Nat Rev Immunol       Date:  2010-09-06       Impact factor: 53.106

3.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion.

Authors:  Yenan T Bryceson; Michael E March; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice.

Authors:  Ricky Cheung; Fran Shen; Joseph H Phillips; Mandy J McGeachy; Daniel J Cua; Paul G Heyworth; Robert H Pierce
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

5.  Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.

Authors:  David G T Hesslein; Rayna Takaki; Michelle L Hermiston; Arthur Weiss; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

6.  JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity.

Authors:  Changlin Li; Baoxue Ge; Matthew Nicotra; Joel N H Stern; Hernan D Kopcow; Xi Chen; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

7.  p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease.

Authors:  Aurore Saudemont; Fabien Garçon; Hakim Yadi; Marta Roche-Molina; Nayoung Kim; Anne Segonds-Pichon; Alfonso Martín-Fontecha; Klaus Okkenhaug; Francesco Colucci
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

Review 8.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

9.  Phosphatidylinositol 3-kinase activation is required to form the NKG2D immunological synapse.

Authors:  Emanuele Giurisato; Marina Cella; Toshiyuki Takai; Tomohiro Kurosaki; Yungfeng Feng; Gregory D Longmore; Marco Colonna; Andrey S Shaw
Journal:  Mol Cell Biol       Date:  2007-10-08       Impact factor: 4.272

10.  Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation.

Authors:  Jennifer D Wu; Catherine L Atteridge; Xuanjun Wang; Tsukasa Seya; Stephen R Plymate
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.